Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome

Thozhukat Sathyapalan, Ahmed Al-Qaissi, Eric S. Kilpatrick, Soha Dargham, Stephen Atkin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: Anti-Müllerian hormone (AMH) is derived from the small antral follicles, and an elevated level has been suggested to add value to the Rotterdam criteria for the diagnosis of PCOS in cases of diagnostic uncertainty. Therefore, the role of AMH in the classical phenotype of PCOS was defined within a Caucasian population. Design: This was a cross-sectional study. Patients: Sixty Five women without PCOS and 110 women with PCOS fulfilling all 3 diagnostic Rotterdam criteria. Measurements: The main outcomes were the utility of serum AMH for the diagnosis of PCOS and its relationship to the metabolic parameters. Results: Anti-Müllerian hormone was increased in PCOS compared to controls (P <.001). Areas under the receiver operator curve showed AMH to be predictive of PCOS (0.76) using a cut-off AMH of 46 pmol/L, which is derived from the 95th percentile of the controls that gave a 41% sensitivity and 86% specificity; an AMH cut-off of 35 pmol/L gave a 55% sensitivity and 79% specificity. Age- and BMI-adjusted multiple logistic regression showed that AMH was more predictive of PCOS independently of either serum testosterone (T) (OR = 4.04; 95% CI 1.42-11.11; P =.007) or free androgen index (FAI) (OR = 3.90; 95% CI 1.40-10.83; P =.009). Conclusion: Whilst an elevated AMH has poor sensitivity, it is fourfold more likely to be associated with a diagnosis of PCOS, and supplementary to biochemical parameters will make a positive diagnosis of PCOS in 22% of patients when neither serum testosterone nor FAI is elevated.

Original languageEnglish
Pages (from-to)258-262
Number of pages5
JournalClinical Endocrinology
Volume88
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Fingerprint

Polycystic Ovary Syndrome
Hormones
Androgens
Testosterone
Serum
Sensitivity and Specificity
Uncertainty
Cross-Sectional Studies
Logistic Models
Phenotype

Keywords

  • androgen
  • anti-müllerian hormone
  • polycystic ovary syndrome
  • rotterdam criteria

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. / Sathyapalan, Thozhukat; Al-Qaissi, Ahmed; Kilpatrick, Eric S.; Dargham, Soha; Atkin, Stephen.

In: Clinical Endocrinology, Vol. 88, No. 2, 01.02.2018, p. 258-262.

Research output: Contribution to journalArticle

Sathyapalan, Thozhukat ; Al-Qaissi, Ahmed ; Kilpatrick, Eric S. ; Dargham, Soha ; Atkin, Stephen. / Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. In: Clinical Endocrinology. 2018 ; Vol. 88, No. 2. pp. 258-262.
@article{06303c8b866442378df7e4f77103746c,
title = "Anti-M{\"u}llerian hormone measurement for the diagnosis of polycystic ovary syndrome",
abstract = "Objective: Anti-M{\"u}llerian hormone (AMH) is derived from the small antral follicles, and an elevated level has been suggested to add value to the Rotterdam criteria for the diagnosis of PCOS in cases of diagnostic uncertainty. Therefore, the role of AMH in the classical phenotype of PCOS was defined within a Caucasian population. Design: This was a cross-sectional study. Patients: Sixty Five women without PCOS and 110 women with PCOS fulfilling all 3 diagnostic Rotterdam criteria. Measurements: The main outcomes were the utility of serum AMH for the diagnosis of PCOS and its relationship to the metabolic parameters. Results: Anti-M{\"u}llerian hormone was increased in PCOS compared to controls (P <.001). Areas under the receiver operator curve showed AMH to be predictive of PCOS (0.76) using a cut-off AMH of 46 pmol/L, which is derived from the 95th percentile of the controls that gave a 41{\%} sensitivity and 86{\%} specificity; an AMH cut-off of 35 pmol/L gave a 55{\%} sensitivity and 79{\%} specificity. Age- and BMI-adjusted multiple logistic regression showed that AMH was more predictive of PCOS independently of either serum testosterone (T) (OR = 4.04; 95{\%} CI 1.42-11.11; P =.007) or free androgen index (FAI) (OR = 3.90; 95{\%} CI 1.40-10.83; P =.009). Conclusion: Whilst an elevated AMH has poor sensitivity, it is fourfold more likely to be associated with a diagnosis of PCOS, and supplementary to biochemical parameters will make a positive diagnosis of PCOS in 22{\%} of patients when neither serum testosterone nor FAI is elevated.",
keywords = "androgen, anti-m{\"u}llerian hormone, polycystic ovary syndrome, rotterdam criteria",
author = "Thozhukat Sathyapalan and Ahmed Al-Qaissi and Kilpatrick, {Eric S.} and Soha Dargham and Stephen Atkin",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/cen.13517",
language = "English",
volume = "88",
pages = "258--262",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome

AU - Sathyapalan, Thozhukat

AU - Al-Qaissi, Ahmed

AU - Kilpatrick, Eric S.

AU - Dargham, Soha

AU - Atkin, Stephen

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objective: Anti-Müllerian hormone (AMH) is derived from the small antral follicles, and an elevated level has been suggested to add value to the Rotterdam criteria for the diagnosis of PCOS in cases of diagnostic uncertainty. Therefore, the role of AMH in the classical phenotype of PCOS was defined within a Caucasian population. Design: This was a cross-sectional study. Patients: Sixty Five women without PCOS and 110 women with PCOS fulfilling all 3 diagnostic Rotterdam criteria. Measurements: The main outcomes were the utility of serum AMH for the diagnosis of PCOS and its relationship to the metabolic parameters. Results: Anti-Müllerian hormone was increased in PCOS compared to controls (P <.001). Areas under the receiver operator curve showed AMH to be predictive of PCOS (0.76) using a cut-off AMH of 46 pmol/L, which is derived from the 95th percentile of the controls that gave a 41% sensitivity and 86% specificity; an AMH cut-off of 35 pmol/L gave a 55% sensitivity and 79% specificity. Age- and BMI-adjusted multiple logistic regression showed that AMH was more predictive of PCOS independently of either serum testosterone (T) (OR = 4.04; 95% CI 1.42-11.11; P =.007) or free androgen index (FAI) (OR = 3.90; 95% CI 1.40-10.83; P =.009). Conclusion: Whilst an elevated AMH has poor sensitivity, it is fourfold more likely to be associated with a diagnosis of PCOS, and supplementary to biochemical parameters will make a positive diagnosis of PCOS in 22% of patients when neither serum testosterone nor FAI is elevated.

AB - Objective: Anti-Müllerian hormone (AMH) is derived from the small antral follicles, and an elevated level has been suggested to add value to the Rotterdam criteria for the diagnosis of PCOS in cases of diagnostic uncertainty. Therefore, the role of AMH in the classical phenotype of PCOS was defined within a Caucasian population. Design: This was a cross-sectional study. Patients: Sixty Five women without PCOS and 110 women with PCOS fulfilling all 3 diagnostic Rotterdam criteria. Measurements: The main outcomes were the utility of serum AMH for the diagnosis of PCOS and its relationship to the metabolic parameters. Results: Anti-Müllerian hormone was increased in PCOS compared to controls (P <.001). Areas under the receiver operator curve showed AMH to be predictive of PCOS (0.76) using a cut-off AMH of 46 pmol/L, which is derived from the 95th percentile of the controls that gave a 41% sensitivity and 86% specificity; an AMH cut-off of 35 pmol/L gave a 55% sensitivity and 79% specificity. Age- and BMI-adjusted multiple logistic regression showed that AMH was more predictive of PCOS independently of either serum testosterone (T) (OR = 4.04; 95% CI 1.42-11.11; P =.007) or free androgen index (FAI) (OR = 3.90; 95% CI 1.40-10.83; P =.009). Conclusion: Whilst an elevated AMH has poor sensitivity, it is fourfold more likely to be associated with a diagnosis of PCOS, and supplementary to biochemical parameters will make a positive diagnosis of PCOS in 22% of patients when neither serum testosterone nor FAI is elevated.

KW - androgen

KW - anti-müllerian hormone

KW - polycystic ovary syndrome

KW - rotterdam criteria

UR - http://www.scopus.com/inward/record.url?scp=85040723199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040723199&partnerID=8YFLogxK

U2 - 10.1111/cen.13517

DO - 10.1111/cen.13517

M3 - Article

VL - 88

SP - 258

EP - 262

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -